Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides.
暂无分享,去创建一个
Darrell J Irvine | Ellis L Reinherz | D. Irvine | E. Reinherz | Mikyung Kim | Haipeng Liu | M. Hanson | Haipeng Liu | Wuhbet Abraham | G. Szeto | Mikyung Kim | Stephanie H. Chen | Melissa C Hanson | Monica P Crespo | Stephanie H Chen | Greg Lee Szeto | W. Abraham | M. P. Crespo
[1] H. Katinger,et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. , 2001, AIDS research and human retroviruses.
[2] D. Montefiori,et al. Rational Design of Membrane Proximal External Region Lipopeptides Containing Chemical Modifications for HIV-1 Vaccination , 2012, Clinical and Vaccine Immunology.
[3] D. Baker,et al. Elicitation of structure-specific antibodies by epitope scaffolds , 2010, Proceedings of the National Academy of Sciences.
[4] S. Zolla-Pazner. A critical question for HIV vaccine development: Which antibodies to induce? , 2014, Science.
[5] C Leclerc,et al. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. , 2000, Vaccine.
[6] Robin A. Weiss,et al. Neutralizing antibodies to HIV-1 induced by immunization , 2013, The Journal of experimental medicine.
[7] J. Binley,et al. An Affinity-Enhanced Neutralizing Antibody against the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 gp41 Recognizes an Epitope between Those of 2F5 and 4E10 , 2007, Journal of Virology.
[8] C. Guzmán,et al. Cyclic di‐nucleotides: new era for small molecules as adjuvants , 2012, Microbial biotechnology.
[9] F. Szoka,et al. Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41. , 2009, Vaccine.
[10] Jamie K. Scott,et al. The Membrane-Proximal External Region of the Human Immunodeficiency Virus Type 1 Envelope: Dominant Site of Antibody Neutralization and Target for Vaccine Design , 2008, Microbiology and Molecular Biology Reviews.
[11] J. Haensler,et al. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants , 2013, Expert review of vaccines.
[12] J. Kappes,et al. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes , 2009, AIDS.
[13] H. Liao,et al. Induction of Antibodies in Rhesus Macaques That Recognize a Fusion-Intermediate Conformation of HIV-1 gp41 , 2011, PloS one.
[14] E. Reinherz,et al. Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface , 2009, Proceedings of the National Academy of Sciences.
[15] K. Überla,et al. Targeting Antibody Responses to the Membrane Proximal External Region of the Envelope Glycoprotein of Human Immunodeficiency Virus , 2012, PloS one.
[16] L. Stamatatos,et al. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. , 2010, Structure.
[17] D. Burton,et al. Antigenic and Immunogenic Study of Membrane-Proximal External Region-Grafted gp120 Antigens by a DNA Prime-Protein Boost Immunization Strategy , 2007, Journal of Virology.
[18] D. Crommelin,et al. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose. , 1997, Biochimica et biophysica acta.
[19] M. Bergeron,et al. Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1. , 2000, Biochimica et biophysica acta.
[20] M Juliana McElrath,et al. Induction of immunity to human immunodeficiency virus type-1 by vaccination. , 2010, Immunity.
[21] E. Reinherz,et al. Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization , 2011, Nature Structural &Molecular Biology.
[22] Critical issues in mucosal immunity for HIV-1 vaccine development. , 2008, The Journal of allergy and clinical immunology.
[23] R. Cox,et al. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice. , 2011, Vaccine.
[24] G Himmler,et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.
[25] B. Haynes,et al. Modulation of Nonneutralizing HIV-1 gp41 Responses by an MHC-Restricted TH Epitope Overlapping Those of Membrane Proximal External Region Broadly Neutralizing Antibodies , 2014, The Journal of Immunology.
[26] S. Moghimi,et al. The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes. , 2006, Biomaterials.
[27] Leaf Huang,et al. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. , 2012, Vaccine.
[28] Peter D. Kwong,et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.
[29] Zhengrong Cui,et al. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses , 2010, Expert review of vaccines.
[30] John A. Robinson,et al. Engineered Synthetic Virus‐Like Particles and Their Use in Vaccine Delivery , 2011, Chembiochem : a European journal of chemical biology.
[31] T. Yasuda,et al. Effect of liposomal model membrane composition on immunogenicity. , 1978, Journal of immunology.
[32] Jessica Yu,et al. Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. , 2007, Vaccine.
[33] Yanrong Wu,et al. DNA-based micelles: synthesis, micellar properties and size-dependent cell permeability. , 2010, Chemistry.
[34] D. Irvine,et al. Immunogenicity of Membrane-bound HIV-1 gp41 Membrane-proximal External Region (MPER) Segments Is Dominated by Residue Accessibility and Modulated by Stereochemistry* , 2013, The Journal of Biological Chemistry.
[35] Martin F. Bachmann,et al. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.
[36] G. Matyas,et al. Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines , 2012, Expert review of vaccines.
[37] Baoshan Zhang,et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.
[38] D. Leaman,et al. Targeting HIV-1 gp41 in close proximity to the membrane using antibody and other molecules. , 2011, Current topics in medicinal chemistry.
[39] Paul W. H. I. Parren,et al. Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.
[40] N. K. Steede,et al. Allocation of Helper T-cell Epitope Immunodominance According to Three-dimensional Structure in the Human Immunodeficiency Virus Type I Envelope Glycoprotein gp120* , 2001, The Journal of Biological Chemistry.
[41] G. Kenner,et al. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. , 2007, Biochimica et biophysica acta.
[42] D. Gerlier,et al. Enhancement of immunogenicity of tumour virus antigen by liposomes: the effect of lipid composition. , 1986, Immunology.
[43] L. Lopalco,et al. Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41. , 2012, Virology.
[44] M. Khan,et al. Targeting to macrophages: role of physicochemical properties of particulate carriers--liposomes and microspheres--on the phagocytosis by macrophages. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[45] Francisco A. Chaves,et al. The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. , 2005, Immunity.
[46] C. Kao,et al. Structure of STING bound to c-di-GMP Reveals the Mechanism of Cyclic Dinucleotide Recognition by the Immune System , 2012, Nature Structural &Molecular Biology.
[47] H. Katinger,et al. Characterization of a trimeric MPER containing HIV-1 gp41 antigen. , 2009, Virology.
[48] V. Brusic,et al. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. , 2008, Immunity.
[49] Jason K. Pontrello,et al. Activating B cell signaling with defined multivalent ligands. , 2007, ACS chemical biology.
[50] David Baltimore,et al. Antibody-based Protection Against HIV Infection by Vectored ImmunoProphylaxis , 2011, Nature.